Yesterday, Sept. 3, 2015, 102 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $16,858,584.42.

Highlighted Stocks Traded by Insiders:

Parexel International (PRXL) - FREE Research Report

Love Richard L, who is Director at Parexel International, sold 1,330 shares at $64.26 on Sept. 3, 2015. Following this transaction, the Director owned 84,350 shares meaning that the stake was reduced by 1.55% with the 1,330-share transaction.

The shares most recently traded at $63.51, down $0.75, or 1.18% since the insider transaction. Historical insider transactions for Parexel International go as follows:

  • 4-Week # shares bought: 455
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 455
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 455
  • 24-Week # shares sold: 5,000

The average volume for Parexel International has been 752,800 shares per day over the past 30 days. Parexel International has a market cap of $3.6 billion and is part of the health care sector and health services industry. Shares are up 16.18% year-to-date as of the close of trading on Thursday.

PAREXEL International Corporation is a biopharmaceutical outsourcing services company. The company has a P/E ratio of 24.4. Currently, there are 5 analysts who rate Parexel International a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRXL - FREE

TheStreet Quant Ratings

rates Parexel International as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Parexel International Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Triple-S Management (GTS) - FREE Research Report

Tonarely-Barreto Francisco, who is Director at Triple-S Management, sold 1,000 shares at $20.80 on Sept. 3, 2015. Following this transaction, the Director owned 8,752 shares meaning that the stake was reduced by 10.25% with the 1,000-share transaction.

The shares most recently traded at $21.30, up $0.50, or 2.34% since the insider transaction. Historical insider transactions for Triple-S Management go as follows:

  • 4-Week # shares sold: 1,100
  • 12-Week # shares sold: 1,100
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 1,100

The average volume for Triple-S Management has been 180,100 shares per day over the past 30 days. Triple-S Management has a market cap of $517.0 million and is part of the financial sector and insurance industry. Shares are down 10.08% year-to-date as of the close of trading on Thursday.

Triple-S Management Corporation, through its subsidiaries, provides various managed care and related products in the commercial and Medicare markets in Puerto Rico, the United States. The company operates through three segments: Managed Care, Life Insurance, and Property and Casualty Insurance. The company has a P/E ratio of 9.0. Currently, there are no analysts who rate Triple-S Management a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GTS - FREE

TheStreet Quant Ratings

rates Triple-S Management as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Triple-S Management Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Kronos Worldwide (KRO) - FREE Research Report

Watson Steven L, who is Chairman of the Board at Kronos Worldwide, bought 26,000 shares at $6.60 on Sept. 3, 2015. Following this transaction, the Chairman of the Board owned 281,352 shares meaning that the stake was boosted by 10.18% with the 26,000-share transaction.

The shares most recently traded at $6.51, down $0.09, or 1.32% since the insider transaction. Historical insider transactions for Kronos Worldwide go as follows:

  • 4-Week # shares bought: 142,232
  • 12-Week # shares bought: 142,232
  • 24-Week # shares bought: 152,232

The average volume for Kronos Worldwide has been 332,100 shares per day over the past 30 days. Kronos Worldwide has a market cap of $781.0 million and is part of the basic materials sector and chemicals industry. Shares are down 47.31% year-to-date as of the close of trading on Thursday.

Kronos Worldwide, Inc. produces and markets titanium dioxide pigments (TiO2) worldwide. The stock currently has a dividend yield of 8.9%. The company has a P/E ratio of 18.2. Currently, there are no analysts who rate Kronos Worldwide a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KRO - FREE

TheStreet Quant Ratings

rates Kronos Worldwide as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Kronos Worldwide Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.